Evidence map›Paper›PMID 30705514›Full record

ArticleJournal of clinical biochemistry and nutrition2019

Astaxanthin, a xanthophyll carotenoid, prevents development of dextran sulphate sodium-induced murine colitis.

Shigeki Sakai, Atsushi Nishida, Masashi Ohno, Osamu Inatomi, Shigeki Bamba, Mitsushige Sugimoto, Masahiro Kawahara, Akira Andoh

Open access · diamondAbstract read
In one paragraph

Article in Journal of clinical biochemistry and nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shigeki SakaiDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu 520-2192, Japan.
Atsushi NishidaDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu 520-2192, Japan.
Masashi OhnoDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu 520-2192, Japan.
Osamu InatomiDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu 520-2192, Japan.
Shigeki BambaDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu 520-2192, Japan.
Mitsushige SugimotoDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu 520-2192, Japan.
Masahiro KawaharaDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu 520-2192, Japan.
Akira AndohDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu 520-2192, Japan.
Shiga University of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Astaxanthin is a xanthophyll carotenoid, which possesses strong scavenging effect on reactive oxygen species. In this study, we examined the effect of astaxanthin on dextran sulfate sodium (DSS)-induced colitis in mice. Experimental colitis was induced by the oral administration of 4% w/v DSS in tap water in C57BL/6J mice. Astaxanthin was mixed with a normal rodent diet (0.02 or 0.04%). Astaxanthin significantly ameliorated DSS-induced body weight loss and reduced the disease activity index. The ameliorating effects was observed in a dose-dependent manner. Immunochemical analyses showed that astaxanthin markedly suppressed DSS-induced histological inflammatory changes (inflammatory cell infiltration, edematous changes and goblet cell depletion). Plasma levels of malondialdehyde and 8-hydroxy-2-deoxyguanosine were significantly reduced by the administration of 0.04% astaxanthin. Astaxanthin significantly suppressed the mucosal mRNA expression of IL-1β, IL-6, TNF-α, IL-36α and IL-36γ. Astaxanthin blocked the DSS-induced translocation of NF-κB p65 and AP-1 (c-Jun) into the nucleus of mucosal epithelial cells, and also suppressed DSS-induced mucosal activation of MAPKs (ERK1/2, p38 and JNK). In conclusion, astaxanthin prevented the development of DSS-induced colitis via the direct suppression of NF-κB, AP-1 and MAPK activation. These findings suggest that astaxanthin is a novel candidate as a therapeutic option for the treatment of inflammatory bowel disease.

Indexed as

carotenoidinflammatory bowel diseasereactive oxygen species

Identifiers

PMID30705514
PMCPMC6348411
OpenAlexW2887777465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.